Gibel announced that the company recently received an invention patent certificate issued by the State Intellectual Property Office. The patent name is “preparation method and application of a novel taxane compound”, patent number: ZL 2024 1 0472632.1. The patent application date is April 13, 2023, and the authorization announcement date is July 28, 2026. The patent holder is Jiangsu Gibel Pharmaceutical Co., Ltd., with a patent term of 20 years. The invention patent provides the use and preparation method of novel taxane compounds, and their use in preparing antitumor drugs. The acquisition of this invention patent will not have a significant impact on the company's recent operations, but it is conducive to improving the company's intellectual property protection system and promoting technological innovation.

Gibel announced that the company recently received an invention patent certificate issued by the State Intellectual Property Office. The patent name is “preparation method and application of a novel taxane compound”, patent number: ZL 2024 1 0472632.1. The patent application date is April 13, 2023, and the authorization announcement date is July 28, 2026. The patent holder is Jiangsu Gibel Pharmaceutical Co., Ltd., with a patent term of 20 years. The invention patent provides the use and preparation method of novel taxane compounds, and their use in preparing antitumor drugs. The acquisition of this invention patent will not have a significant impact on the company's recent operations, but it is conducive to improving the company's intellectual property protection system and promoting technological innovation.